BBHC
ALDR

Brown Brothers Harriman & Co’s Alder Biopharmaceuticals ALDR Stock Holding History

Brown Brothers Harriman & Co’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-114
Closed -$2K – 919
2016
Q4 		$2K Hold
114
– – ﹤0.01% 841
2016
Q3 		$4K Hold
114
– – ﹤0.01% 717
2016
Q2 		$3K Buy
+114
New +$3.08K ﹤0.01% 775

Other funds holding ALDR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Brown Brothers Harriman & Co's ALDR Position: Q1 2017 in Review

Brown Brothers Harriman & Co sold out of Alder Biopharmaceuticals (ALDR) in Q1 2017, closing a stake of 114 shares — an estimated $2K sold.

Brown Brothers Harriman & Co first reported a position in ALDR in Q2 2016 and held it in 3 quarters. The position peaked at $4K in Q3 2016. 142 funds tracked by Wall St. Rank hold ALDR as of Q1 2017.

  • Brown Brothers Harriman & Co reported no remaining Alder Biopharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 114 Alder Biopharmaceuticals shares in Q1 2017, an estimated $2K.
  • Brown Brothers Harriman & Co first reported a position in Alder Biopharmaceuticals in Q2 2016 and held it in 3 quarters.
  • Brown Brothers Harriman & Co's Alder Biopharmaceuticals position peaked at $4K in Q3 2016.
  • 142 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q1 2017.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2017, filed 12 May 2017.